Scarica l'app Stockscreener
0.4202
8.65%
-0.0398
Precedente Chiudi:
$0.46
Aprire:
$0.4143
Volume 24 ore:
997.15K
Relative Volume:
1.36
Capitalizzazione di mercato:
$446.72K
Reddito:
-
Utile/perdita netta:
$-12.91M
Rapporto P/E:
-0.00444
EPS:
-94.5617
Flusso di cassa netto:
$-12.02M
1 W Prestazione:
-77.53%
1M Prestazione:
-83.19%
6M Prestazione:
-97.36%
1 anno Prestazione:
-99.43%
Intervallo 1D:
$0.373
$0.4202
Intervallo di 1 settimana:
$0.373
$1.8439
Portata 52W:
$0.373
$80.00
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Nome
Silexion Therapeutics Corp
Settore
Industria
Telefono
972-8-6286005
Indirizzo
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.4202 | 482.76K | 0 | -12.91M | -12.02M | -94.56 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Silexion Therapeutics Corp Borsa (SLXN) Ultime notizie
Silexion Therapeutics (SLXN) seeks huge share boost and reverse split to stay on Nasdaq - Stock Titan
Silexion Q2 EPS $(5.17) misses $(2.12) estimate; loss widens - scanx.trade
Silexion Therapeutics Raises $35 Million in August Public Offering - Minichart
Silexion Therapeutics Corp 2Q 2026: Net loss $3.55M, EPS $(12.41) — 10-Q Summary - TradingView
Silexion Initiates Phase 2/3 Pancreatic Cancer Trial on July 29 - Minichart
Silexion Therapeutics Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Silexion Reports $3.6 Million Second-Quarter Net Loss as SIL204 Trial Starts - Quiver Quantitative
Silexion Therapeutics reports Q2 2026: $3.6M Q2 net loss, $2.2M cash at June 30 - TradingView
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo! Finance Canada
Silexion Completes 1-for-10 Reverse Share Split - Minichart
Top Silexion Therapeutics CorpWarrant (SLXNW) Competitors 2026 - MarketBeat
Form 8K Silexion Therapeutics Corp For: 13 August By Investing.com - Investing.com Nigeria
Silexion Therapeutics Executes Reverse Share Split Amid Strain - TipRanks
Silexion Therapeutics Closes Public Offering and Strengthens Equity - TipRanks
Silexion Therapeutics Corp (SLXN) investors report 0% holding but retain warrants - Stock Titan
Silexion Therapeutics Corp SEC Filing (Aug 12, 2026) - Stock Titan
Silexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-Bell - marketscreener.com
Silexion prices $2.5M offering to fund KRAS cancer trial - Dealroom
Silexion Therapeutics prices $2.5M public offering at $0.65 By Investing.com - Investing.com Nigeria
Silexion Therapeutics prices $2.5M public offering at $0.65 - Investing.com
Silexion Intends to Use Offering Proceeds for Pancreatic Trial - Stock Titan
Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and Warrants - Quiver Quantitative
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering - GlobeNewswire
Immunotherapy’s Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - TipRanks
Immunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN) - Benzinga
Immunotherapy's Biggest Blind Spot Is A $7 Billion Market. Silexion May Have A Way In (NASDAQ: SLXN) - Menafn
Form 8K Silexion Therapeutics Corp For: 10 August By Investing.com - Investing.com Nigeria
Silexion Updates SIL204 Clinical and Regulatory Roadmap - TipRanks
Silexion Therapeutics (SLXN US): Synthetic Expert Call Transcript (10 Aug 2026) - Smartkarma
Silexion Therapeutics publishes corporate deck spotlighting SIL204 siRNA program targeting KRAS-driven cancers - Bitget
Maxim Group Maintains Silexion Therapeutics(SLXN.US) With Hold Rating - 富途牛牛
IPO Databook: Silexion Therapeutics (SLXN US)Aug 2026 - Smartkarma
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock Titan
Silexion unveils key SIL204 KRAS preclinical findings - TipRanks
Silexion to present preclinical data on SIL-204 at GI cancer event - Investing.com
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers - The Manila Times
Silexion Therapeutics Reports Preclinical Data Showing SIL204 Immune-Sensitizing Effects in KRAS-Mutant Cancer Cells - Quiver Quantitative
Silexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock Titan
Silexion Therapeutics Restores Nasdaq Audit Committee Compliance - TipRanks
Silexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingView
Silexion Therapeutics Announces Board Member Resignation - TipRanks
Silexion Therapeutics Warrant (SLXNW) Holds at $0.02 as Range-Bound Trading PersistsVolatility Stop - dars.gov.et
Biomotion Sciences Ordinary Shares (NASDAQ: SLXN) Stock Price, News & Analysis - Kalkine
Amnon Peled resigns from Silexion Therapeutics board effective Aug 1, 2026 - TradingView
Maxim Downgrades Silexion Therapeutics to Hold From Buy - marketscreener.com
Silexion Therapeutics Corp Warrant (SLXNW) Holds Near Par After Modest DeclineHead and Shoulders - dars.gov.et
Silexion Begins Phase 2/3 Trial in Pancreatic Cancer - TipRanks
Silexion Activates First Site in Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - tipranks.com
Silexion Therapeutics Successfully Initiates Phase 2/3 - GlobeNewswire
Silexion Therapeutics Initiates Phase 2/3 Trial for Pancreatic Cancer Drug Candidate - Moomoo
Silexion Activates First Site In Phase 2/3 Trial Targeting KRAS-Driven Pancreatic Cancer (NASDAQ: SLXN) - Menafn
Silexion Therapeutics Corp Azioni (SLXN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):